Table 2.
Best response and time to progression (TTP) ratios.
| Best response | Group 1 (n = 16) | Group 2 (n = 32) | ||||
|---|---|---|---|---|---|---|
| Complete response | 0 (0%) | 1 (6%) | ||||
| D029 | endometrial carcinoma | CHEK2 | ||||
| Partial response | 3 (19%) | 2 (6%) | ||||
| D018 | gallbladder, adenocarcinoma | BRCA2 | D007 | breast, IDC | ATM | |
| D040 | cholangiocarcinoma | BRCA2 | D030 | NEC | ATM | |
| D047 | PEComa | BRCA2 | ||||
| Stable disease | 5 (31%) | 18 (56%) | ||||
| Non-CR/non-PD | 1 (6%) | 0 (0%)* | ||||
| D026 | cervix, adenocarcinoma | BRCA2 | ||||
| Progressive disease | 7 (43%) | 11 (34%) | ||||
| Response maintained > 6 m | 5 (31%) | 12 (38%) | ||||
| 4 patients achieving PR, non-CR- non-PD + | 3 patients achieving an objective response + | |||||
| D041 | glioma | BRCA2 | D001 | chondrosarcoma | FANCA | |
| D008 | pancreas adenocarcinoma | BRIP, RAD51 | ||||
| D013 | ovarian sex cord-stromal tumour | CHEK2 | ||||
| D017 | chondrosarcoma | ATR | ||||
| D021 | small intestine adenocarcinoma | CDK12, RAD51 | ||||
| D027 | colorectal adenocarcinoma | RAD51 | ||||
| D032 | breast, IDC | ATM | ||||
| D034 | papillary thyroid | ATM, NBN | ||||
| D037 | liposarcoma | CDK12 | ||||
| TTP2/TTP1 > 1.3 | 4 (31%) | 7 (25%) | ||||
| D026 | Cervix, adenocarcinoma | BRCA2 | D004 | uveal melanoma | BAP1 | |
| D041 | Glioma | BRCA2 | D007 | breast, IDC | ATM | |
| D045 | Pancreas, adenocarcinoma | BRCA2 | D008 | pancreas, adenocarcinoma | BRIP, RAD51C | |
| D047 | PeCOMA, uterus | BRCA2 | D015 | colorectal, adenocarcinoma | FANCI | |
| D021 | small intestine, adenocarcinoma | CDK12, RAD51 | ||||
| D030 | NEC | ATM | ||||
| D034 | papillary thyroid | NBN, ATM | ||||
IDC infiltrating ductal carcinoma, NEC neuroendocrine carcinoma, PEComa perivascular epithelioid cell tumour.
Underlined study ID indicates patients who achieved both an objective response and TTP2/TTP1 > 1.3. *D029 had non-measurable disease at baseline but achieved a CR based on subsequent scans.